17 October 2024 The chronic obstructive pulmonary disease (COPD) market in the seven major markets (7MM) is set to grow from $11.5 billion in 2023 to $30.8 billion in 2033, driven by the launch of the first biologic for COPD and other pioneering pipeline agents.
As the European Parliament prepares for the confirmation hearings of the new Commissioners, the Open Trade Coalition is reiterating its call for a bold and open EU trade policy, according to a posting on the European Federation of Pharmaceutical Industries and Associations (EFPIA) website. 18 October 2024
After a couple of negative decisions, the US Food and Drug Administration (FDA) has approved Vyalev (foscarbidopa and foslevodopa) as the first and only subcutaneous 24-hour infusion of levodopa-based therapy for the treatment of motor fluctuations in adults with advanced Parkinson's disease (PD). 18 October 2024
Gan & Lee Pharmaceuticals as reported that its three investigational drugs - GZR18, GZR4, and GZR101 - achieved positive results in Phase II diabetes trials. 17 October 2024
A new group of British Members of Parliament (MPs) and peers have written to the Chancellor urging her to protect and promote the UK’s world-leading life sciences sector in the government's first Budget, due on October 30. 17 October 2024
The US Food and Drug Administration (FDA) has updated the US label for French pharma major Sanofi’s Flublok (Influenza Vaccine) to include data from a new safety study involving pregnant women. 17 October 2024
Chengdu Baiyu Pharmaceutical yesterday announced that it has entered into an exclusive license agreement with Swiss pharma giant Novartis for a small molecule anti-tumor asset. 17 October 2024
Shionogi has announced new data at IDWeek 2024 from PROVE (Retrospective Cefiderocol Chart Review), the largest global real-world evidence study of Fetroja/Fetcroja (cefiderocol), an innovative siderophore cephalosporin. 17 October 2024
Sanofi has entered into an agreement with Orano Med, a subsidiary of the Orano Group, to advance the development of radioligand therapies for rare cancers. 17 October 2024
ViiV Healthcare, the specialist HIV company majority owned by GSK, today announced the presentation of new real-world evidence and implementation data showing the effectiveness, adherence, and quality-of-life improvement of Apretude (cabotegravir long-acting (CAB LA)) for HIV pre-exposure prophylaxis (PrEP). 16 October 2024
Jaguar Health today announced the US launch of Gelclair, the only Food and Drug Administration (FDA)-approved mucoadhesive on the market indicated for the management of pain caused by oral mucositis 16 October 2024
Netherlands-based life sciences venture capital firm Forbion has raised more than 2 billion euros ($2.2 billion) across its two newest funds. 16 October 2024
The American Lung Association Research Institute has announced a $22 million research investment in 2024, marking one of the largest lung health research programs in the USA. 16 October 2024
US pharma major Eli Lilly has announced a strategic collaboration with two UK government departments and the devolved nations to tackle significant population health challenges, including exploring new models to better care for people living with obesity. 16 October 2024
TenNor Therapeutics, a Suzhou-based clinical-stage biotech company, has announced the initial closing of a series E financing round, raising over 300 million yuan ($41 million). 16 October 2024
Switzerland-based Novocure saw its shares rise 10% yesterday and leap a further 24% to $22.05 pre-market, after the company received a new US regulatory approval for its key product Optune Lua. 16 October 2024
Shares of Spanish drugmaker PharmaMar leapt more than 28% to 63.70 euros today, after it announced positive clinical trial findings for its combo lung cancer treatment, under development with USA-based Jazz Pharmaceuticals, which rose 4.2%. 15 October 2024
US pharma major Eli Lilly recently announced top-line results of tirzepatide from its SURMOUNT-1 Phase III clinical trial, which has stirred up the outlook for the pharmacological weight management market. 13 May 2022
The European pharma industry has released a new report offering recommendations to improve outcomes for people living with a cardiovascular disease (CVD) in the region. 13 May 2022
The US Food and Drug Administration has approved Radicava ORS (edaravone) oral suspension for the treatment of adults with amyotrophic lateral sclerosis (ALS). 13 May 2022
In the USA and in Europe, interest in the potential for artificial intelligence to transform different aspects of the life sciences industry is at an all-time high. 12 May 2022
For researchers unaffiliated with an academic library, it can be hard to find, organize, and share scientific papers. Can a new tool address this gap? 12 May 2022
The World Health Organization’s COVID-19 Technology Access Pool (C-TAP) and the Medicines Patent Pool (MPP) today finalized a licensing agreement with the USA’s National Institutes of Health (NIH) for the development of several innovative therapeutics, early-stage vaccines and diagnostic tools for COVID-19. 12 May 2022
Switzerland’s EffRx Pharmaceuticals, Slovenia’s Medis, Russia’s Orpharm, Brazil’s OrphanDC, and Dubai-based Vector Pharma, announced today the newly-formed World Orphan Drug Alliance (WODA). 12 May 2022
In line with most analysts’ expectations, Germany’s Merck KGaA has reported group sales of 5.2 billion euros ($5.4 billion) for the first quarter, an increase of 12.2%. 12 May 2022
Tokyo’s Taiho Pharmaceutical, a business of Japanese drug major Otsuka Pharmaceutical, has agreed to buy part of Cullinan Oncology, thereby regaining rights to a candidate it out-licensed in 2019. 12 May 2022
Netherlands-based Qiagen has signed agreements to acquire a 96% majority ownership stake in Blirt SA, a manufacturer of recombinant enzymes for the life science industry based in Gdansk, Poland. 12 May 2022
Shares in Miami-based Veru were 4% higher at lunchtime Wednesday on the back of some good news from the US Food and Drug Administration (FDA). 11 May 2022
Japanese ophthalmology specialist Santen Pharmaceutical has received approval of Verkazia (ciclosporin eye drops) from the National Medical Products Administration (NMPA) in China through its Chinese legal entity for the treatment of severe vernal keratoconjunctivitis (VKC) in children and adolescents aged 4 years and above. 11 May 2022
The US Food and Drug Administration’s Center for Drug Evaluation and Research (CDER) has announced the launch of the new Accelerating Rare disease Cures (ARC) Program. 11 May 2022
Shares of Denmark-based CNS specialist Lundbeck were up 7% at 161.30 Danish kroner in early afternoon trading, after it released a strong set of first-quarter 2022 financials. 11 May 2022
The USA’s medicine cost watchdog the Institute for Clinical and Economic Review (ICER) today released a Final Evidence Report assessing the comparative clinical effectiveness and value of the following outpatient treatments for COVID-19: 10 May 2022
Italian drugmaker Recordati saw its shares gain 2.1% to 42.31 euros by early afternoon, as the company released first-quarter 2022 financial results. 10 May 2022
German pharma major Bayer has reported a strong start to the year, with group sales up 14.3% at 14.6 billion euros ($15.4 billion), including 4.6 billion euros from pharmaceuticals, a 5.9% increase. 10 May 2022
The US Food and Drug Administration yesterday announced the availability of a draft guidance for industry, Benefit-Risk Considerations for Product Quality Assessments. 10 May 2022
Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news
Company Spotlight
Dewpoint is a biotech company pioneering the application of biomolecular condensate biology – the science studying the organization of biomolecules within membrane-less compartments – towards the development of a new generation of therapeutics to address diseases of high unmet need.